Switch theme
Sign up to access all valuation multiples
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
1961
18.1K+
LTM Revenue $2.8B
LTM EBITDA $458M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diagnosticos America has a last 12-month revenue (LTM) of $2.8B and a last 12-month EBITDA of $458M.
In the most recent fiscal year, Diagnosticos America achieved revenue of $2.7B and an EBITDA of $349M.
Diagnosticos America expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diagnosticos America valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8B | XXX | $2.7B | XXX | XXX | XXX |
| Gross Profit | $2.8B | XXX | $737M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $458M | XXX | $349M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $232M | XXX | $177M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | -$130M | XXX | -$211M | XXX | XXX | XXX |
| Net Margin | -5% | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Diagnosticos America's stock price is BRL 2 (or $0).
Diagnosticos America has current market cap of BRL 2.0B (or $349M), and EV of BRL 13.5B (or $2.4B).
See Diagnosticos America trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $349M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Diagnosticos America has market cap of $349M and EV of $2.4B.
Diagnosticos America's trades at 0.9x EV/Revenue multiple, and 6.8x EV/EBITDA.
Equity research analysts estimate Diagnosticos America's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diagnosticos America has a P/E ratio of -2.7x.
See valuation multiples for Diagnosticos America and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $349M | XXX | $349M | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 13.4x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -26.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiagnosticos America's last 12 month revenue growth is 7%
Diagnosticos America's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $31K for the same period.
Diagnosticos America's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diagnosticos America's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diagnosticos America and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $31K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnosticos America acquired XXX companies to date.
Last acquisition by Diagnosticos America was XXXXXXXX, XXXXX XXXXX XXXXXX . Diagnosticos America acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Diagnosticos America founded? | Diagnosticos America was founded in 1961. |
| Where is Diagnosticos America headquartered? | Diagnosticos America is headquartered in Brazil. |
| How many employees does Diagnosticos America have? | As of today, Diagnosticos America has 18.1K+ employees. |
| Is Diagnosticos America publicy listed? | Yes, Diagnosticos America is a public company listed on BVMF. |
| What is the stock symbol of Diagnosticos America? | Diagnosticos America trades under DASA3 ticker. |
| When did Diagnosticos America go public? | Diagnosticos America went public in 2004. |
| Who are competitors of Diagnosticos America? | Similar companies to Diagnosticos America include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Diagnosticos America? | Diagnosticos America's current market cap is $349M |
| What is the current revenue of Diagnosticos America? | Diagnosticos America's last 12 months revenue is $2.8B. |
| What is the current revenue growth of Diagnosticos America? | Diagnosticos America revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Diagnosticos America? | Current revenue multiple of Diagnosticos America is 0.9x. |
| Is Diagnosticos America profitable? | Yes, Diagnosticos America is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diagnosticos America? | Diagnosticos America's last 12 months EBITDA is $458M. |
| What is Diagnosticos America's EBITDA margin? | Diagnosticos America's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Diagnosticos America? | Current EBITDA multiple of Diagnosticos America is 5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
